The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme

The binding and cytochrome P45051 (CYP51) inhibition properties of a novel antifungal compound, VT-1161, against purified recombinant Candida albicans CYP51 (ERG11) and Homo sapiens CYP51 were compared with those of clotrimazole, fluconazole, itraconazole, and voriconazole. VT-1161 produced a type I...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Warrilow, A. G. S., Hull, C. M., Parker, J. E., Garvey, E. P., Hoekstra, W. J., Moore, W. R., Schotzinger, R. J., Kelly, D. E., Kelly, S. L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2014
Témata:
Experimental Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249504/
https://ncbi.nlm.nih.gov/pubmed/25224009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03707-14
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky